{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:54:27Z","timestamp":1785128067560,"version":"3.55.0"},"reference-count":34,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JIR"],"DOI":"10.2147\/jir.s240593","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T01:30:14Z","timestamp":1654047014000},"page":"3259-3267","source":"Crossref","is-referenced-by-count":6,"title":["Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":true,"given":"Florenzo","family":"Iannone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-1179","authenticated-orcid":true,"given":"Alberto","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","unstructured":"Centers for Disease Control and Prevention. Rheumatoid Arthritis (RA). [cited 2021, January 29]. Available from: https:\/\/www.cdc.gov\/arthritis\/basics\/rheumatoid-arthritis.html. Accessed May 4, 2022."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC201901010","volume":"170","author":"Sparks","year":"2019","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.10731","volume":"48","author":"Sokka","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10067-004-0976-6","volume":"24","author":"West","year":"2005","journal-title":"Clin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/ard.2003.019034","volume":"64","author":"Puolakka","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref11","unstructured":"European public assessment report Remsima. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima. Accessed August 27, 2021."},{"key":"ref12","unstructured":"European public assessment report Benepali. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/benepali. Accessed August 27, 2021."},{"key":"ref13","unstructured":"European public assessment report Amgevita. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/amgevita. Accessed August 27, 2021."},{"key":"ref14","unstructured":"Italian Medicines Agency (AIFA). The use of drugs in Italy National Report, Year 2015 (OSMED report). Available from: https:\/\/www.aifa.gov.it\/uso-dei-farmaci-in-italia. Accessed August 27, 2021."},{"key":"ref15","unstructured":"Italian Medicines Agency (AIFA). The use of drugs in Italy National Report, Year 2020 (OSMED report). Available from: https:\/\/www.aifa.gov.it\/uso-dei-farmaci-in-italia. Accessed August 27, 2021."},{"key":"ref16","first-page":"847","volume":"33","author":"Westhovens","year":"2006","journal-title":"J Rheumatol"},{"key":"ref17","unstructured":"European Medicines Agency. Remsima summary of product characteristics. [cited 2021 January 29]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remsima-epar-product-information_en.pdf. Accessed May 4, 2022."},{"key":"ref18","unstructured":"US Food and Drug Administration. Highlights of prescribing information, inflectra (infliximab-dyyb). [cited 2021 January 29]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125544s008lbl.pdf. Accessed May 4, 2022."},{"key":"ref19","unstructured":"European Medicines Agency. Assessment report on extension(s) of marketing authorisation: remsima. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/remsima-h-c-2576-x-0062-epar-assessment-report-variation_en.pdf. Accessed August 30, 2021."},{"key":"ref20","unstructured":"European Medicines Agency. Assessment report on extension(s) of marketing authorisation: remsima. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/remsima-h-c-2576-ii-0082-epar-assessment-report-variation_en.pdf. Accessed August 30, 2021."},{"key":"ref21","unstructured":"Remsima Product Information. 30\/04\/2021 Remsima - EMEA\/H\/C\/002576 - II\/0095. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima. Accessed August 30, 2021."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/s10165-009-0195-8","volume":"19","author":"Takeuchi","year":"2009","journal-title":"Mod Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/FTD.0b013e3181cc6fef","volume":"32","author":"Mulleman","year":"2010","journal-title":"Ther Drug Monit"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/ard.2004.030452","volume":"64","author":"Wolbink","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/btt.2009.3099","volume":"3","author":"Perdriger","year":"2009","journal-title":"Biologics"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","volume":"60","author":"Westhovens","year":"2021","journal-title":"Rheumatology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/1744666X.2020.1858803","volume":"17","author":"Caporali","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13075-021-02487-x","volume":"23","author":"Combe","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"102849","DOI":"10.1016\/j.autrev.2021.102849","volume":"20","author":"D\u2019Amico","year":"2021","journal-title":"Autoimmun Rev"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e0166443","DOI":"10.1371\/journal.pone.0166443","volume":"11","author":"Mazzuoli","year":"2016","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1038\/s41598-021-94504-x","volume":"11","author":"S\u00e1nchez-Piedra","year":"2021","journal-title":"Sci Rep"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.3390\/ijms20184350","volume":"20","author":"Graudal","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S2468-1253(20)30392-7","volume":"6","author":"Verma","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/flgastro-2020-101760","volume":"13","author":"McGoran","year":"2021","journal-title":"Frontline Gastroenterol"}],"container-title":["Journal of Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=81185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=81185","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T01:30:22Z","timestamp":1654047022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/subcutaneously-administered-infliximab-in-the-management-of-rheumatoid-peer-reviewed-fulltext-article-JIR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2147\/jir.s240593","relation":{},"ISSN":["1178-7031"],"issn-type":[{"value":"1178-7031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}